Long-term follow-up of persons diagnosed with multidrug-resistant TB in Chennai, India, 2013–2020
Diya Surie, M.K. Sathyanarayanan, J. Lavanya, Jonathan P. Smith, Surendran K. Shanmugam, Sembulingam Tamilzhalagan, A. Selvara, Gayathri Ramesh, et al. (15 authors)
The International Journal of Tuberculosis and Lung Disease · 2024-01
Abstract
India has the largest number of multidrug-resistant TB (MDR-TB) cases, defined as Mycobacterium tuberculosis resistant to at least isoniazid (INH) and rifampicin (RIF).1 However, less than half of all persons with MDR-TB in India successfully complete treatment.1 Although initial end-of-treatment outcomes offer a standardised time point to assess the effect of treatment, these tend to underestimate the overall burden of unfavourable long-term outcomes among persons treated for TB.2,3 The long-term outcomes of persons diagnosed with MDR-TB in India, including the proportion with recurrent TB disease or mortality, are unknown. This analysis was conducted under programmatic conditions in a high-burden setting, with no regular check-ups after treatment. The results can be used to show the burden of recurrent illness and death following treatment, and can be used as a benchmark to measure improvement.
MeSH terms
- Term (time)
- Medicine
- Multiple drug resistance
- Tuberculosis
- Environmental health
- Pediatrics